Acadian Asset Management
ORIC icon

Acadian Asset Management’s Oric Pharmaceuticals ORIC Stock Holding History

Acadian Asset Management’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,679
Closed -$33K – 2172
2026
Q1 		$33K Buy
+2,679
New +$30.4K ﹤0.01% 1900
2024
Q4 		– Sell
-2,309
Closed -$23K – 2022
2024
Q3 		$23K Buy
+2,309
New +$22.8K ﹤0.01% 1960
2023
Q4 		– Sell
-22,691
Closed -$137K – 1780
2023
Q3 		$137K Sell
22,691
-147,797
-87% -$1.21M ﹤0.01% 1258
2023
Q2 		$1.32M Buy
170,488
+39,833
+30% +$226K 0.01% 814
2023
Q1 		$744K Buy
130,655
+2,804
+2% +$14.7K ﹤0.01% 954
2022
Q4 		$752K Hold
127,851
– – ﹤0.01% 920
2022
Q3 		$408K Buy
127,851
+13,635
+12% +$54.6K ﹤0.01% 1044
2022
Q2 		$511K Buy
114,216
+108,709
+1,974% +$434K ﹤0.01% 964
2022
Q1 		$29K Buy
+5,507
New +$49.6K ﹤0.01% 1525

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management's ORIC Position: Q2 2026 in Review

Acadian Asset Management sold out of Oric Pharmaceuticals (ORIC) in Q2 2026, closing a stake of 2,679 shares — an estimated $33K sold.

Acadian Asset Management first reported a position in ORIC in Q1 2022 and held it in 9 quarters. The position peaked at $1.32M in Q2 2023. 180 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Acadian Asset Management reported no remaining Oric Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Acadian Asset Management sold 2,679 Oric Pharmaceuticals shares in Q2 2026, an estimated $33K.
  • Acadian Asset Management first reported a position in Oric Pharmaceuticals in Q1 2022 and held it in 9 quarters.
  • Acadian Asset Management's Oric Pharmaceuticals position peaked at $1.32M in Q2 2023.
  • 180 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.